Conferencia: Cannabinoides no psicotrópicos en inflamación
Doctor in Medicine and Surgery from the University of Cordoba (1986, Spain). He made his first postdoctoral stay at Tufts University (Boston, 1987-90) investigating the differential regulation of cytokines in Th1 and Th2 cells. Later, he carried out a second postdoctoral stay at the Pasteur Institute (Paris, 1992-94) studying the regulation of NF-kB by the Tax protein of HTLV-1. He is currently Professor of Immunology at the University of Cordoba and director of the BIO304 group of the PAIDI.
Since 2012 he also directs the IMIBIC Inflammation and Cancer group (GC04), a mixed group of basic and clinical researchers. He has directed 26 doctoral theses (six extraordinary prizes) and his main lines of research are focused on the development of new cannabinoid derivatives with potential application in chronic and degenerative inflammatory. Some of these studies have resulted in the discovery of a clinical candidates currently under development with orphan drug status in EU and USA (the cannabinoaminoquinones VCE-004.8 and VCE-003.2). Moreover VCE-004.8 is the API of EHP-101 that has completed a Phase I clinical study ( NCT03745001) and initiation of Phase II studies in SSc patients have been initiated in 2020 ( NCT04166552).
He is the author of near to 250 scientific articles in international journals, book chapters and patents. He belongs to the editorial board of the journals Planta Medica and Fitoterapia and is founder of the companies VivaCell Biotechnology (2003) (now Emerald Health Biotechnology) and InnoHealth Group S.L. (2015) acquired by Evonik Industries AG (2020).
More than 194 publications in peer-review journals, H index: 51 and 7975 citations: google scholar)
Last Publications (selected articles in cannabinoids and endocannabinoids):
  1. Caprioglio D, Mattoteia D, Pollastro F, Negri R, Lopatriello A, Chianese G, Minassi A, Collado JA, Munoz E, Taglialatela-Scafati O, Appendino G. The Oxidation of Phytocannabinoids to Cannabinoquinoids. J Nat Prod. 2020 May 22;83(5):1711-1715.
  2. Palomares B, Garrido-Rodriguez M, Gonzalo-Consuegra C, Gómez-Cañas M, Saen-Oon S, Soliva R, Collado JA, Fernández-Ruiz J, Morello G, Calzado MA, Appendino G, Muñoz E. Δ9-Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: Role of PPARγ and CB1 receptors. Br J Pharmacol. 2020 Jun 8;177(17):4034–54.
  3. Navarrete C, García-Martin A, Garrido-Rodríguez M, Mestre L, Feliú A, Guaza C, Calzado MA, Muñoz E. Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis. Neurobiol Dis. 2020 Sep;143:104994.

©2020 Powered by CEDIA. All Rights Reserved.